These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 19606161)
1. [0.05% cyclosporine a for treatment of chronic severe ocular surface disease]. Nochez Y; Denoyer A; Pisella PJ Can J Ophthalmol; 2009 Aug; 44(4):406-11. PubMed ID: 19606161 [TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Pucci N; Caputo R; Mori F; De Libero C; Di Grande L; Massai C; Bernardini R; Novembre E Int J Immunopathol Pharmacol; 2010; 23(3):865-71. PubMed ID: 20943058 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Stevenson D; Tauber J; Reis BL Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092 [TBL] [Abstract][Full Text] [Related]
5. Clinical review: topical ophthalmic use of cyclosporin A. Utine CA; Stern M; Akpek EK Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287 [TBL] [Abstract][Full Text] [Related]
6. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Barber LD; Pflugfelder SC; Tauber J; Foulks GN Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833 [TBL] [Abstract][Full Text] [Related]
7. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Saini M; Dhiman R; Dada T; Tandon R; Vanathi M Eye (Lond); 2015 Jun; 29(6):808-14. PubMed ID: 25857609 [TBL] [Abstract][Full Text] [Related]
8. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Toker E; Asfuroğlu E Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Keklikci U; Soker SI; Sakalar YB; Unlu K; Ozekinci S; Tunik S Jpn J Ophthalmol; 2008; 52(5):357-362. PubMed ID: 18991035 [TBL] [Abstract][Full Text] [Related]
10. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Ozcan AA; Ersoz TR; Dulger E Cornea; 2007 Oct; 26(9):1035-8. PubMed ID: 17893529 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome. Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302 [TBL] [Abstract][Full Text] [Related]
12. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799 [TBL] [Abstract][Full Text] [Related]
13. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Wilson SE; Perry HD Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588 [TBL] [Abstract][Full Text] [Related]
14. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889 [TBL] [Abstract][Full Text] [Related]
15. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Sall K; Stevenson OD; Mundorf TK; Reis BL Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324 [TBL] [Abstract][Full Text] [Related]
16. [Cyclosporine eye drops: A 4-year retrospective study (2009-2013)]. Kauss Hornecker M; Charles Weber S; Brandely Piat ML; Darrodes M; Jomaa K; Chast F J Fr Ophtalmol; 2015 Oct; 38(8):700-8. PubMed ID: 26371985 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye. Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702 [TBL] [Abstract][Full Text] [Related]
18. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. Salib GM; McDonald MB; Smolek M J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793 [TBL] [Abstract][Full Text] [Related]
20. [Prognosis and treatment of Vernal keratoconjunctivitis in pediatric age: pilot study on 197 patients]. Spadavecchia L; Fanelli P; Tesse R; Rizzo G; Procoli U; Bellizzi M; Armenio L Minerva Pediatr; 2010 Jun; 62(3):239-44. PubMed ID: 20467374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]